Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Dose Response ◽

Controlled Trial ◽

Japanese Patients ◽

Phase 2 ◽

Efficacy And Safety ◽

Response Efficacy ◽

Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30311-0 ◽

2019 ◽

Vol 7 (11) ◽

pp. 834-844 ◽

Cited By ~ 32

Author(s):

Ildiko Lingvay ◽

Andrei-Mircea Catarig ◽

Juan P Frias ◽

Harish Kumar ◽

Nanna L Lausvig ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Review for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v2/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽

Decision letter for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v2/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽

Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study)

Diabetologia ◽

10.1007/s00125-009-1622-2 ◽

2010 ◽

Vol 53 (3) ◽

pp. 419-428 ◽

Cited By ~ 92

Author(s):

H. Sone ◽

◽

S. Tanaka ◽

S. Iimuro ◽

S. Tanaka ◽

...

Keyword(s):

Type 2 Diabetes ◽

Lifestyle Intervention ◽

Diabetes Complications ◽

Controlled Trial ◽

Japanese Patients ◽

Review for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v1/review1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽

Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV randomised controlled trial (PRIME-V study)

BMJ Open ◽

10.1136/bmjopen-2016-015766 ◽

2017 ◽

Vol 7 (5) ◽

pp. e015766 ◽

Cited By ~ 3

Author(s):

Masaya Koshizaka ◽

Ko Ishikawa ◽

Takahiro Ishikawa ◽

Kazuki Kobayashi ◽

Minoru Takemoto ◽

...

Keyword(s):

Type 2 Diabetes ◽

Visceral Fat ◽

Controlled Trial ◽

Efficacy And Safety ◽

Dipeptidyl Peptidase 4 ◽

Fat Reduction ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Review for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v2/review2 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽

Author response for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v2/response1 ◽

2019 ◽

Author(s):

Linong Ji ◽

Eun Seok Kang ◽

XiaoLin Dong ◽

Ling Li ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Author Response ◽

Efficacy And Safety ◽

Review for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v1/review2 ◽

2019 ◽

Author(s):

Michael C. d'Emden

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽

Decision letter for "Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin‐Naïve People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial"

10.1111/dom.13936/v1/decision1 ◽

2019 ◽

Keyword(s):

Type 2 Diabetes ◽

Insulin Glargine ◽

Controlled Trial ◽

Asia Pacific ◽

Efficacy And Safety ◽